Abstract
Objectives: The advent of CFTR modulator therapy represents an unparalleled opportunity to improve quality and length of life for over 90% of CF patients. Yet list prices for these drugs have been set at ~$300,000 per year, representing an enormous barrier to access. As such we sought to appraise international pricing and reimbursement of Kaftrio® to identify gaps in access, and to explore potential solutions to how wider treatment availability can be achieved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
